US Start-Up Phlow Receives Further Capital Injection To Fund Essential Medicines

Cash Will Be Used For Multiple Key Initiatives

Fresh from its $812m government contract to help prevent shortages of essential medicines and shield the US market from global competition, domestic start-up Phlow Corporation has received further financial backing.

Made_In_USA_Flag
Domestic manufacturing and production of essential medicines, considering heavy reliance on China and other countries for API supplies, remains a hot topic in the US • Source: Shutterstock

The US-government backed Phlow Corporation has closed a $20m series A financing, which the firm says will further aid its key initiatives directed towards accelerating US manufacturing for medicines at risk of shortage, including those useful in response to the COVID-19 pandemic.

“This injection of additional strategic capital will be used by Phlow to fund initiatives including building the company’s commercial business...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business